Pharmafile Logo

World Health Organization

dengue fever mosquito

Novartis endorses Kigali Declaration by investing $250m for tropical diseases

1.7 billion people suffer from neglected tropical diseases worldwide, and there are 241 million cases of malaria

- PMLiVE

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

The licence and collaboration agreements will provide 135 countries access to cefiderocol

- PMLiVE

New virtual health and care report from WHO and Novartis calls for ‘critical action’

The report analysis shows how COVID-19 has changed virtual health and care policies in 23 countries

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

WHO releases estimates of 14.9 million excess deaths during COVID-19 pandemic

The estimates show the full death toll caused directly or indirectly by the COVID-19 pandemic between 1 January 2020 and 31 December 2021

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

Longitude Prize in final stage of deciding recipients of £8m prize

The prize will be awarded to a team of innovators who develop a point-of-care diagnostic test that will help combat antimicrobial-resistant infections

- PMLiVE

The IMC unites health industry professionals to combat antibiotic resistant infections

The coalition has formed a new call to action in addressing the way infections are managed across healthcare systems

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Omicron prompts global action

A new variant of concern discovered in southern Africa is quickly spreading around the world, prompting government to take action

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

By Henry Skinner, Chief Executive Officer of the AMR Action Fund

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links